Waters Corporation has introduced the Xevo MRT P10 Mass Spectrometer, a high-resolution Quadrupole Time-of-Flight (QToF) System designed for high-throughput multiomics, bioanalysis, and biopharmaceutical laboratories.
The Xevo MRT P10 MS delivers up to 20x greater MS/MS sensitivity than its predecessor, along with industry-leading speed and expanded acquisition modes to comprehensively support both targeted and untargeted analysis in a single benchtop platform. The system is designed to accelerate biomarker discovery and validation whilst supporting the identification of disease pathways and therapeutic targets across large-cohort biomedical research and epidemiology studies.
Speed and sensitivity at scale
With acquisition speeds twice as fast as its predecessor, it is the fastest benchtop high-resolution mass spectrometry (HRMS) system currently available. The new system supports rapid throughput, alongside exceptional resolution and mass accuracy, delivering the highest data quality and confidence. When combined with the DESI XS ion source, rapid spatial analysis is unlocked down to the cellular level at up to 200 Hz, increasing throughput six-fold whilst maintaining image quality.
Broad applicability across multiomics and drug discovery
The Xevo MRT P10 MS is well suited to support long-term growth across multiomics, including proteomics, lipidomics, and metabolomics, as well as biopharmaceutical analysis and drug discovery. The instrument unlocks new workflows in high-throughput, deep proteome discovery by combining greater sensitivity with ultra-fast acquisition rates and advanced acquisition modes. Researchers can now confidently detect of low-abundance peptides, achieve comprehensive protein identification and support rapid separations at scale.
In comparative lipid profiling by LC-MS/MS, the Xevo MRT P10 MS identifies up to 40% more lipids than the most competitive alternative systems. These enhancements support more comprehensive biological interpretation in multiomics driven research and ultimately drive deeper levels of disease understanding.
